Kyxata

What Is Kyxata?

Kyxata (carboplatin) is a platinum-based drug indicated in adults as part of a combination regimen, for the initial treatment of advanced ovarian carcinoma, or as a single-agent for the treatment of ovarian carcinoma recurrent after prior chemotherapy.

What Are Side Effects of Kyxata?

Side effects of Kyxata include:

• nausea and vomiting (may be severe),
• other gastrointestinal adverse reactions,
• numbness and tingling in extremities,
• hair loss,
• weakness/lethargy,
• pain,
• anemia,
• low white blood cell count (leukopenia, neutropenia),
• low platelets (thrombocytopenia),
• low magnesium (hypomagnesemia),
• low sodium (hyponatremia),
• low phosphates (hyperphosphatasemia), and
• low calcium (hypocalcemia).

Seek medical care or call 911 at once if you have the following serious side effects:

• Serious eye symptoms such as sudden vision loss, blurred vision,tunnel vision,eye painor swelling, or seeing halos around lights;
• Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheadedness, or passing out;
• Severe headache,confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

Dosage for Kyxata

The dose of Kyxata for the initial treatment of advanced ovarian carcinoma is 300 mg/m2 -OR- AUC of 4 mg/mL·min to 6 mg/mL·min intravenously in combination with cyclophosphamide on Day 1 every 4 weeks for each cycle. Administer up to six cycles or until disease progression or unacceptable toxicity occurs.

The dose of Kyxata for treatment of recurrent advanced ovarian carcinoma as a single agent is 360 mg/m2 -OR- AUC of 4 mg/mL·min to 6 mg/mL·min intravenously on Day 1 every 4 weeks for each cycle until disease progression or unacceptable toxicity occurs.

Kyxata In Children

The safety and effectiveness of Kyxata in pediatric patients have not been established.

What Drugs, Substances, or Supplements Interact with Kyxata?

Kyxata may interact with other medicines such as:

• aminoglycosides.

Tell your doctor all medications and supplements you use.

Kyxata During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Kyxata; it can harm a fetus. The pregnancy status of patients who can become pregnant should be verified prior to initiating Kyxata. Patients who can become pregnant are advised to use effective contraception during treatment with Kyxata and for 6 months after the last dose. Patients with partners who can become pregnant are advised to use effective contraception during treatment with Kyxata and for 3 months after the last dose. It is unknown if Kyxata passes into breast milk. Because of the potential for serious adverse reactions in breastfed children from Kyxata, breastfeeding is not advised during treatment with Kyxata and for 1 week after the last dose.

Additional Information

Our Kyxata (carboplatin) Injection, for Intravenous Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.